The oral mucosal proteome: perturbation in HIV infection and Candida co infection
Project Number5R01DE017514-02
Contact PI/Project LeaderCHALLACOMBE, STEPHEN J
Awardee OrganizationKING'S COLLEGE LONDON
Description
Abstract Text
DESCRIPTION (provided by applicant): This multidisciplinary application supports a strategy of combining patient-oriented research with the science based investigation of disease causation. The overall aim is to understand the mechanisms that apparently protect the oral epithelium from HIV infection. The long-term objective is to understand the basis of copathogenicity in the immunocompromised host leading to the delivery of more effective therapies. We hypothesize that HIV directly affects the oral epithelial proteome, leading to alterations that promote colonization and infection of the co-pathogen Candida. The specific aims are: 1) To fully characterize the constituents of the oral epithelium that protects the oral mucosa from HIV and Candida infection. Using oral and vaginal epithelial models, and human and macaque samples, the canonical receptors for both HIV and Candida will be investigated by flow cytometry. The epithelial proteome in the presence or absence of HIV and Candida will be then be fully characterized in order to identify protective or susceptibility factors to HIV and Candida infection in these mucosae. Saliva will be applied to the models to investigate the contribution of innate secretory factors present in oral fluids that may inhibit HIV or Candida infection Transcript profiling, quantitative RT-PCR, and Luminex protein assays will be performed to support the proteomic data. 2) To characterize the innate TLR-associated proteomic response elicited by human epithelium during HIV and Candida infection. The HIV- and C. a/b/cans-induced epithelial cytokine, chemokine, TLR1-10 and signaling pathway expression profiles will first be characterized in oral and vaginal epithelial models using proteomics. The PMN-dependent TLR-mediated protection mechanism against oral C. albicans infection will then be fully characterized using transcript profiling, real-time RT-PCR, confocal and immunoelectron microscopy, and siRNAi. Relevance: HIV/AIDS is most commonly transmitted through mucosal membranes. In some circumstances, the oral tissues are exposed to HIV but rarely become infected. Understanding the mechanism by which the oral cavity is apparently protected from infection could lead to the development of therapies to protect other mucosal tissues such as the vagina from infection and transmission of the virus. This could also lead to therapies for the treatment of the co-infections associated with HIV such as oral Thrush.
National Institute of Dental and Craniofacial Research
CFDA Code
121
DUNS Number
231876178
UEI
NMH2NELG8E88
Project Start Date
17-April-2006
Project End Date
31-March-2011
Budget Start Date
01-April-2007
Budget End Date
31-March-2008
Project Funding Information for 2007
Total Funding
$262,170
Direct Costs
$242,750
Indirect Costs
$19,420
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Dental and Craniofacial Research
$262,170
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DE017514-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DE017514-02
Patents
No Patents information available for 5R01DE017514-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DE017514-02
Clinical Studies
No Clinical Studies information available for 5R01DE017514-02
News and More
Related News Releases
No news release information available for 5R01DE017514-02
History
No Historical information available for 5R01DE017514-02
Similar Projects
No Similar Projects information available for 5R01DE017514-02